Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes to Help Improve Drug Discovery
Axol Bioscience Ltd. announced that its hiPSC-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation.
[Signal Transduction and Targeted Therapy] Scientists provide an update on recent clinical applications using either human pluripotent stem cells or mesenchymal stem cells derived from bone marrow, adipose tissue, or the umbilical cord for the treatment of human diseases.
[Scientific Reports] The authors suggested a novel strategy to treat triple negative breast cancer (TNBC) using mesenchymal stem cell-derived extracellular vesicles to transform the behaviors and cellular communication of TNBC cells with other non-cancer cells related to tumorigenesis and metastasis.
[Cancer Discovery] Researchers combined CAR T19 with the FDA-approved BCL-2-inhibitor, venetoclax, and demonstrated in vivo synergy in venetoclax-sensitive non-Hodgkin lymphoma.